Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Prospidium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1984

[Treatment with intratumoral prospidium chloride of cancer of the mammae induced by N-nitrosomethylurea in the rat].

Wistar rats bearing N-nitrosomethylurea-induced mammary tumors received intratumoral injections of prospidium chloride or saline. Each tumor with 30-100 mm2 (the product of the two largest perpendicular diameters) received 20 mg of prospidium chloride diluted in 100 microliter of saline, and increasing amounts of 20 mg of the product in the same volume for every additional 100 mm2 or fraction of tumor. After a week the treatment was repeated in the same way. Control rats received only saline without prospidium chloride. No significant differences were observed regarding the tumor area, total tumor area/rat, and body weight when comparing the rats receiving prospidium chloride and the control rats. Prospidium chloride does not show any direct oncolytic effect upon the experimental model employed.

Animals↗
PubMed1983

Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio.

Four different cytostatic compounds (prospidium chloride, peptichemio, dacarbazine and mithramycin) have been assayed for their effect on lymphoblastic transformation of spleen cells from mice. The drugs did not affect cell viability at concentrations lower than 0.1-0.2 micrograms/ml (peptichemio and mithramycin) or than 10-20 micrometers/ml (prospidium chloride and dacarbazine). Except for peptichemio, which did not show any marked effect, these cytostatics acted more actively on B cells than on T cells at concentrations of drug not affecting lymphocyte viability. Mithramycin was the most active inhibitor of the mitogen-induced DNA synthesis in the cell. Concentrations of this drug to inhibit the blastogenic response to 50% (IC50) were lower than 0.1 microgram/ml. Inhibition of mitogenesis was less pronounced in the case of dacarbazine (IC50 = 50 and 10 micrograms/ml for T and B cells, respectively), prospidium chloride (IC50 greater than 50 and 50 micrograms/ml for T and B cells) and peptichemio (IC50 = 0.25 and 0.5 microgram/ml for T and B cells, respectively.

Animals↗
PubMed1983

[Type A adenocarcinoma grafted into C3H/he-M mice subjected to treatment with various antineoplastic agents. I. Biological study].

The biological modifications in C3H/he-M mice treated with vincristine, prospidium chloride and adriamycin are studied. A significative reduction of the tumor volume was observed with prospidium chloride and adriamycin treatment. The index of tumour growth inhibition (I0) is very high and corroborates the obtained results. The histopathological and ultrastructural studies will be published later.

Adenocarcinoma↗
PubMed1983

[Type A adenocarcinoma grafted into C3H/he mice subjected to treatment with various antineoplastic agents. II. Histopathological and ultrastructural study].

We studied the histopathological and ultrastructural modifications which the adenocarcinoma type A grafted to C3 H/he-M mice manifested on being treated with vincristine, prospidium chloride and adriamycin. With M/O the tumors treated with prospidium chloride and adriamycin showed a greater proportion of connective stroma and numerous extensive parenchymatous necrosis. Ultrastructurally, in these groups, atypical mitoses were observed with multiple chromosomal fragmentations which can be related to the pharmacological action mechanism. A decrease in the number of viral particles was seen throughout the treatment.

Adenocarcinoma↗
PubMed2001

New experimental model of multiple myeloma.

NSO/1 (P3x63Ay 8Ut) and SP20 myeloma cells were inoculated to BALB/c OlaHsd mice. NSO/1 cells allowed adequate stage-by-stage monitoring of tumor development. The adequacy of this model was confirmed in experiments with conventional cytostatics: prospidium and cytarabine caused necrosis of tumor cells and reduced animal mortality.

Animals↗
PubMed1984

[In vitro sensitivity of epidermoid lung cancer to cytostatics depending upon the degree of tumor differentiation].

In vitro sensitivity of epidermoid lung carcinoma to chemotherapeutic agents in short-term cultures versus degree of tumor differentiation was evaluated for the following drugs: 5-fluorouracil, methotrexate, olivomycin, bleomycin, carminomycin, adriablastin, prospidium chloride, vincristine, thiophosphamide, novembichine and photrine. The results of the investigation using resected material from 77 cases of histologically confirmed epidermoid lung carcinoma failed to establish any relationship between the parameters under study for all above drugs except vincristine. However, tumors showing similar levels of differentiation demonstrated different sensitivity to certain drugs.

Antineoplastic Agents↗
PubMed1994

Study of anticancer drug interaction with DNA by means of particle-induced desorption mass spectrometry: prospydine and deoxyguanosine-5'-monophosphate.

Using 252CF particle desorption mass spectrometry, the interaction between an antitumour drug prospydine (Pro) and deoxyguanosine-5'-monophosphate (pdG) has been studied. The adduct which corresponds to a peak at m/z 524.5 and which occurs as a result of the particular degradation of Pro during its alkylating of pdG has been found.

Antineoplastic Agents↗
PubMed1980

Overadditive chemotherapeutic synergism of prospidine and inosine when given sequentially to the Sarcoma 180 implanted intramuscularly.

The chemotherapeutic effectiveness of prospidine monotherapy on the Sarcoma 180 implanted i.m. was compared with several prospidine/inosine combinations. The chemotherapeutic action of the combination was enhanced overadditively when inosine was given 6 h after prospidine. This particular combination caused not only a significant curative action and tumor inhibition as compared with prospidine monotherapy, but also decreased the toxic effects.

Animals↗
PubMed1994

Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: a controlled 6-month clinical trial.

Twenty-seven patients with highly active, refractory rheumatoid arthritis (RA) were treated with the new anti-rheumatic drug prospidine, in view of selecting the optimum pulse regimen and comparing its short-term use with methotrexate (MTX). Prospidine was administered intravenously 500 mg every 3-5 days in the hospital and then monthly. Fifteen patients received MTX (30 mg/week intravenously in hospital and then monthly. Fifteen patients received MTX (30 mg/week intravenously in hospital and then orally 7.5-15 mg/week). The randomisation code was 2:1. We assessed 7 clinical and 4 lab data. The clinical improvement was noticed statistically after 2-4 weeks in 85% prospidine-patients and sustained up to 6 months in 73% (cp. 40% and 57% by the MTX). Only in the prospidine patients were a significant reduction of the mean daily prednisolone dose and the levels of rheumatoid factor and immune complexes observed. Prospidine and MTX had a similar incidence of side effects (39% and 43%), but all drop-outs in prospidine pulse were due to lack of response (26%) and to initial intolerance (4%). Drop-outs in MTX pulse were connected both with drug toxicity (14%) and with lack of response (7%). Alternate prospidine pulse, as highly anti-inflammatory, rapidly acting and well-tolerated regimen, may be used in treating severe forms of RA.

Adolescent↗
PubMed1984

Effect of prospidine administered at different times of the day on the development and growth of N-nitrosomethylurea-induced mammary tumors in Wistar rats.

The chemotherapeutic effectiveness of intraperitoneal administration of prospidine (50 mg/kg per day during the initial 14 days of study) was evaluated, on a circadian basis, on the N-nitrosomethylurea (NMU)-induced mammary tumors in female rats. Untreated rats showed a progressive increase in the mean tumor area and total tumor area/rat. At the end of treatment the average tumor area and total tumor area/rat in the animals treated at 0800, 1400 and 2000 h were significantly lower than the values in the control group by week 2. By weeks 3 and 4 the mean tumor area and total tumor area in all groups of treated rats were significantly lower than those in the untreated animals. The mean tumor area by weeks 5 and 6 in the animals treated at 0800 h were significantly lower than in the group treated at 0200 h, and the mean value by week 6 in the group treated at 1400 h was significantly lower than those from the groups treated either at 2000 h or 0200 h. The mean total tumor area/rat in rats treated at 1400 h was, by week 6, significantly lower than in animals treated either at 2000 h or 0200 h. A transient reduction in body weight was registered at the end of prospidine treatment.

Animals↗
PubMed1996

Determination of the anticancer drug prospidin in human tissue by high-performance capillary electrophoresis using derivatization.

A high-performance capillary electrophoresis (HPCE) method is described for the quantitative determination of the anticancer drug prospidin in human tissue after its derivatization with diethyldithiocarbamic acid sodium salt (DDTC). It was found that absorption of prospidin and its derivatives on the capillary wall due to the strong positive charge in the drug molecules could be eliminated by increasing the methanol content in the run buffer up to 50% and increasing the pH value up to 11.2. While studying the conditions of the interaction between prospidin and DDTC, a molar excess of the latter of 1:9 and 1.5 h of reaction time were found to be enough for complete derivatization. Sample preparation included homogenization of freshly cut papilloma species and deproteinization by methanol addition. Detection was by ultraviolet (UV) absorption at 254 nm. Due to its speed and high performance in separation, HPCE was found to be well suited for the fast checking of drug therapy in clinical practice.

Antineoplastic Agents↗
PubMedDate not supplied

Comparison of the different types of "laparoscopic total hysterectomy".

STUDY OBJECTIVE: To review the operative outcomes among different types of laparoscopic total hysterectomy (LH) classified according to the Munro and Parker classification system. DESIGN: Prospective observational cohort study (Canadian Task Force classification II). SETTING: 6 major public hospitals in Hong Kong. PATIENTS: 143 patients underwent LH in a 6-month period. INTERVENTIONS: Type I to type IV LH according to the Munro and Parker classification system. MEASUREMENTS AND MAIN RESULTS: We studied 56 type I, 49 type II, 25 type III, and 13 type IV LH. The median operative time was 105 minutes, which was significantly longer in the type IV LH group (160 minutes). The median blood loss was significantly higher in the type I LH group (300 mL). The incidence of urinary tract infection in type I LH was 8.9%, which was significantly higher than other LH groups. The overall operative complication rate was 20.3%, which was highest in the type III hysterectomy group (36%), although the difference did not reach statistical significance among the various types of hysterectomy groups. CONCLUSION: There has been a change from abdominal hysterectomy to LH in the past decades, and it is time for us to explore the best type of LH. Our findings suggest that type I LH is associated with significantly more blood loss and urinary tract infection; whereas type IV LH is associated with significantly longer operating time. However, we still cannot conclude which is the best type of LH until results from a randomized controlled trial will become available.

Adult↗
PubMed2002

Primary cutaneous plasmacytoma: a clinicopathological study of two cases with a long-term follow-up and review of the literature.

BACKGROUND: Primary cutaneous plasmacytoma (PCP) is a rare type of cutaneous B-cell lymphoma arising primarily in the skin and derived from clonally expanded plasma cells with a various degrees of maturation and atypia. The disease is rare with only 30 cases reported so far. METHODS: Two cases of PCP with long-term follow-up of 17 and 15 years are presented. RESULTS AND CONCLUSIONS: Both patients were men with nodular lesions on the face. Histologically, the lesions were composed predominantly of variably maturated plasma cells with monotypic expression of immunoglobulin (Ig) lambda chains. Polymerase chain reaction for IgH genes did not reveal clonal rearrangement. Our cases are discussed in the context of previously reported cases of PCP with a long-term follow-up. We also include a review of all cases of PCP with known tumor progression earlier in the course of the disease (local relapse or visceral spread) to determine the clinical course of this primary cutaneous lymphoma.

Adult↗
PubMed1980

[Results of treatment in cases with bilateral retinoblastoma (author's transl)].

Immediate and late results of treatment in 132 cases with bilateral retinoblastoma (the children were aged between two months and six years) were analyzed. Combined treatment comprised enucleation of the more affected eye, further chemotherapy, X-ray treatment and photocoagulation. Cytostatic compounds used were "TET" (analogous to "TEM") and "Prospidin". Of the treated children, 44.8% are alive; the period of observation ranged from seven to 16 years.

Child↗
PubMedDate not supplied

[Relationship between means of administration, concentration in the blood, organ distribution and excretion of prespidin-14C from the body].

Blood content, distribution among organs and tissues and passage from the organism of prospidine-C14 in rats, following its introduction per os and application to the skin in the form of an ointment, were studied. With these modes of introduction it is shown that prospidine and/or products of its biotransformation are capable of relatively quickly penerating through the wall of the gastro-intestinal tract and skin. However, specific radioactivity in the organs in such cases is scores of time lower than with intravenous administration. In case of the peroral introduction of the compound 72.3 per cent of the amount of the compound and/or of its metabolites administered are eliminated via the gastro-intestinal tract in two days.

Administration, Oral↗